Journal for ImmunoTherapy of Cancer

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response

Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia

The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system

Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series

Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment

Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1\u2009T cell responses

Chemotherapy accelerates immune-senescence and functional impairments of Vδ2pos T cells in elderly patients affected by liver metastatic colorectal cancer

Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy

Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer

Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma

Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab

Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12

Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies

Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis

Hypothesis: does adrenalitis caused by immune checkpoint-inhibitors put melanoma patients at an elevated risk for recurrence?

Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer

TLR9 acts as a sensor for tumor-released DNA to modulate anti-tumor immunity after chemotherapy

Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial

Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model

Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors

Pericardial effusion under nivolumab: case-reports and review of the literature

Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody

Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition

Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature

Correction to: Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1

Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism